Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681574 | 0.95 | PDE4B (0.88) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3681019 | 0.91 | PDE4B (0.81) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3678790 | 0.91 | PDE4B (0.82) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3677082 | 0.90 | PDE4B (0.87) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3674701 | 0.90 | PDE4B (0.79) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3678716 | 0.90 | PDE4B (0.82) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3670582 | 0.90 | PDE4B (0.80) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3675954 | 0.89 | PDE4B (0.89) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3676392 | 0.89 | PDE4B (1.00) | PDE4BKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL3672993 | 0.89 | PDE4B (1.00) | PDE4BKDM4EALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745646-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745646-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745646-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008006051-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885KDM4E 1489/4885ALDH1A1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.